Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer (original) (raw)
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
Eric Raymond
British Journal of Cancer, 2014
View PDFchevron_right
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
Jasmina Makarevic
Journal of cellular and molecular medicine, 2015
View PDFchevron_right
Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas
Gilles Pagès
Cancer research, 2017
View PDFchevron_right
Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma
Jessica zucman-rossi
Acta oncologica (Stockholm, Sweden), 2018
View PDFchevron_right
Sunitinib therapy in renal cell carcinoma
Paul Russo
BJU International, 2008
View PDFchevron_right
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
Lawrence Fong
Cancer, 2011
View PDFchevron_right
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
John Barnard
British Journal of Cancer, 2016
View PDFchevron_right
Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation
Masato Fujisawa
BJU International, 2013
View PDFchevron_right
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
Laura Nevado
British Journal of Cancer, 2014
View PDFchevron_right
Role of fibroblast growth factor receptor in sunitinib-resistant renal cell carcinoma
Claudia Chavez-Munoz
Biotarget
View PDFchevron_right
Antiangiogenic treatments and mechanisms of action in renal cell carcinoma
Eric Raymond
Investigational New Drugs, 2012
View PDFchevron_right
Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma
Sergio Bracarda
European Urology Supplements, 2009
View PDFchevron_right
Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma
Giorgio Santoni
BioMed Research International, 2013
View PDFchevron_right
New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Vincenzo Gentile
Reviews on Recent Clinical Trials, 2008
View PDFchevron_right
Sunitinib activates Axl signaling in renal cell cancer
Henk Dekker
International Journal of Cancer, 2016
View PDFchevron_right
Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
Samet YAMAN
Future Oncology, 2019
View PDFchevron_right
Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response
Martijn Meijerink
Clinical Cancer Research, 2008
View PDFchevron_right
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
David Bearss
2011
View PDFchevron_right
Predictive Factors for Sunitinib Treatment Response in Advanced Renal Cell Carcinoma Are We Really Making Steps Forward
ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY
ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY, 2015
View PDFchevron_right
Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study
Peter Goebell
Journal of Clinical Oncology, 2014
View PDFchevron_right
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials
Thomas E Hutson
Clinical genitourinary cancer, 2006
View PDFchevron_right
Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC
Jeannette Oosterwijk-wakka
Neoplasia (New York, N.Y.), 2015
View PDFchevron_right
Combination targeted therapy in advanced renal cell carcinoma
Igor Puzanov
Cancer, 2009
View PDFchevron_right
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Loukas Kontovinis
BMC Cancer, 2009
View PDFchevron_right
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
Pascal Wolter, Patrick Schöffski, Paul Clement
Annals of Oncology, 2006
View PDFchevron_right
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma
Aude Salomon
British Journal of Cancer
View PDFchevron_right
A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
Sarah R Haile
Oncology, 2012
View PDFchevron_right
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma
Daniele Minardi, Guendalina Lucarini
Anticancer research
View PDFchevron_right
Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new
Jeffrey P MacKeigan
The Lancet Oncology, 2010
View PDFchevron_right
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Agnieszka Buraczewska
Medical oncology (Northwood, London, England), 2011
View PDFchevron_right
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Robert Roskoski
Biochemical and Biophysical Research Communications, 2007
View PDFchevron_right
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study
Konstantinos Papazisis, Aristotelis Bamias
Medical Oncology, 2011
View PDFchevron_right